Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iDose TR Phase 3 Trial (GC-012)
NCT03868124Phase 3Completed
- Sponsor
- Glaukos Corporation
- Start
- Sep 2018
- Primary completion
- Jun 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of travoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Glaukos Corporation. Started Sep 2018; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03868124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03868124.